Ricerc@Sapienza

Background: At the earliest stage of Alzheimer's disease (AD), although patients are still asymptomatic, cerebral alterations have already been triggered. In addition to beta amyloid (Aβ) accumulation, both glial alterations and neuroinflammation have been documented at this stage. Starting treatment at this prodromal AD stage could be a valuable therapeutic strategy. AD requires long-term care; therefore, only compounds with a high safety profile can be used, such as the new formulation containing palmitoylethanolamide and luteolin (co-ultra PEALut) already approved for human use.

Alzheimer's disease is a devastating neurological illness with a high economic burden. The additional morbidity associated with social issues that arises along with the course of this disorder increases the need for a clear understanding of its etiopathogenesis thus allowing an implementation of novel pharmacological strategies. Despite astrocytes have been long described to actively participate in the regulation of brain circuits, available information is still poor. Even less information is available about their precise role in the pathogenesis of illness.